Publications by authors named "Esther Pronker"
Self-Centric and Altruistic Unmet Needs for Ebola: Barriers to International Preparedness.
Disaster Med Public Health Prep
August 2016
Objective: Barriers to international Ebola preparedness may be elucidated by identifying heterogeneities in arguments to invest in countermeasures during "peace time."
Methods: For each patent family (related patent documents that differed only by limited alterations to the same invention) concerning Ebola and published until the end of 2014 the oldest patent document was analyzed. Grounded theory coding identified 5 unmet needs for (1) vaccines and therapies, (2) control of outbreaks in endemic areas, (3) detection and control of outbreaks in nonendemic areas, (4) better understanding of filoviruses, and (5) protection against bioterrorism.
A quantitative method is presented to rank strengths, weaknesses, opportunities, and threats (SWOT) of modified vaccinia virus Ankara (MVA) as a platform for pre-pandemic and pandemic influenza vaccines. Analytic hierarchy process (AHP) was applied to achieve pairwise comparisons among SWOT factors in order to prioritize them. Key opinion leaders (KOLs) in the influenza vaccine field were interviewed to collect a unique dataset to evaluate the market potential of this platform.
View Article and Find Full Text PDFAt present, industries within the health and life science sector are moving towards one another resulting in new industries such as the medical nutrition industry. Medical nutrition products are specific nutritional compositions for intervention in disease progression and symptom alleviation. Industry convergence, described as the blurring of boundaries between industries, plays a crucial role in the shaping of new markets and industries.
View Article and Find Full Text PDFArticle Synopsis
- Vaccination is the most effective way to fight infectious diseases, but the pharmaceutical industry faces a productivity gap where investment does not meet expected outcomes.
- A study compiled data on vaccine projects from 1998 to 2009, finding that vaccines typically take around 10.71 years to develop, with a market entry probability of only 6%.
- Pandemic influenza vaccines seem more lucrative, and there are notable differences in risk profiles: vaccines for acute diseases are lower risk compared to those for chronic diseases, with further research needed on cancer and other specialized vaccines.
Aim: Procedures for verification of data from clinical studies are intended to maintain reliability for clinical trial results. Guidelines or legislations relating to clinical data management are of limited value and no study has yet demonstrated its effectiveness.
Method: Sponsor queries and dual entry procedures from one CRO on three different phase I trials are analysed on content, impact and cost.